Combination
-
【Product for Licensing】siRNA Therapeutics Targeting PD-L1 for HBV
If you are interested in this asset or need more information, please kindly contact DrugTimes BD Team at BD@drugtimes.cn, we will present the non-confidential deck to you for review asap. Many thanks!~
-
As the 10th anniversary of approval approaches，Keytruda adds ‘potential’ performance to Merck
DrugTimes will follow up on this subject. Please stay tuned
